loading
Cullinan Therapeutics Inc stock is traded at $8.645, with a volume of 594.56K. It is down -0.40% in the last 24 hours and up +9.43% over the past month. Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
See More
Previous Close:
$8.68
Open:
$8.57
24h Volume:
594.56K
Relative Volume:
1.32
Market Cap:
$510.23M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-2.3428
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
+10.69%
1M Performance:
+9.43%
6M Performance:
-35.72%
1Y Performance:
-62.07%
1-Day Range:
Value
$8.27
$8.85
1-Week Range:
Value
$7.73
$8.85
52-Week Range:
Value
$6.85
$24.76

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name
Name
Cullinan Therapeutics Inc
Name
Phone
617-410-4650
Name
Address
ONE MAIN STREET, CAMBRIDGE
Name
Employee
111
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
CGEM's Discussions on Twitter

Compare CGEM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CGEM
Cullinan Therapeutics Inc
8.645 460.90M 0 -153.16M -134.48M -3.69
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-24-24 Initiated UBS Buy
May-01-24 Initiated Stifel Buy
Apr-15-24 Initiated William Blair Outperform
Feb-15-24 Initiated Wedbush Outperform
Jun-15-23 Initiated TD Cowen Outperform
Nov-21-22 Initiated BTIG Research Buy
Apr-27-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Feb-02-21 Initiated Evercore ISI Outperform
Feb-02-21 Initiated Morgan Stanley Equal-Weight
Feb-02-21 Initiated SVB Leerink Outperform
Feb-01-21 Initiated H.C. Wainwright Buy
View All

Cullinan Therapeutics Inc Stock (CGEM) Latest News

pulisher
08:45 AM

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology | CGEM Stock News - GuruFocus

08:45 AM
pulisher
08:25 AM

Cullinan Therapeutics IncTaiho Oncology And Cullinan Therapeutics Publish Positive Rezilient1 Trial Results - marketscreener.com

08:25 AM
pulisher
08:21 AM

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - PR Newswire

08:21 AM
pulisher
04:04 AM

ProShare Advisors LLC Acquires 4,124 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

04:04 AM
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference | CGEM Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference - The Globe and Mail

May 29, 2025
pulisher
May 26, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by D. E. Shaw & Co. Inc. - Defense World

May 26, 2025
pulisher
May 24, 2025

Ameriprise Financial Inc. Raises Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

May 24, 2025
pulisher
May 22, 2025

Cullinan Therapeutics (CGEM) Reveals Promising Phase 2b Results - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology Announce Positive Results from REZILIENT1 Trial of Zipalertinib in Advanced Lung Cancer Patients - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 - GlobeNewswire

May 22, 2025
pulisher
May 21, 2025

Northern Trust Corp Raises Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

May 21, 2025
pulisher
May 20, 2025

115,000 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Acquired by BNP Paribas Financial Markets - Defense World

May 20, 2025
pulisher
May 15, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stake Boosted by Price T Rowe Associates Inc. MD - Defense World

May 15, 2025
pulisher
May 14, 2025

Cullinan Therapeutics (CGEM) Projected to Announce Quarterly Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 13, 2025

Cullinan Therapeutics (CGEM): UBS Lowers Price Target but Mainta - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Cullinan Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 13, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Price Target Lowered to $24.00 at UBS Group - Defense World

May 13, 2025
pulisher
May 12, 2025

UBS Adjusts Price Target on Cullinan Therapeutics to $24 From $30, Maintains Buy Rating - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Cullinan Therapeutics (CGEM) Price Target Revised by UBS Analyst - GuruFocus

May 12, 2025
pulisher
May 10, 2025

Cullinan Therapeutics Inc Reports Q1 2025 EPS Below Estimates wi - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Cullinan Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 10, 2025
pulisher
May 09, 2025

Cullinan Therapeutics: Q1 Earnings Snapshot - New Haven Register

May 09, 2025
pulisher
May 09, 2025

Dimensional Fund Advisors LP Acquires 295,467 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

May 09, 2025
pulisher
May 08, 2025

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

Cullinan Oncology (CGEM) Projects Financial Runway through 2028 | CGEM Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Cullinan Therapeutics (CGEM) Advances Autoimmune and Oncology Programs | CGEM Stock News - GuruFocus

May 08, 2025
pulisher
May 07, 2025

Cullinan Therapeutics (CGEM) Advances Autoimmune and Oncology Pr - GuruFocus

May 07, 2025
pulisher
May 07, 2025

MetLife Investment Management LLC Acquires 2,217 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

May 07, 2025
pulisher
May 07, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Holdings Lifted by Wells Fargo & Company MN - Defense World

May 07, 2025
pulisher
May 05, 2025

Upcoming US clinical trial will test CLN-978 as Sjögren’s treatment - Sjogren's Syndrome News

May 05, 2025
pulisher
May 03, 2025

Invesco Ltd. Buys 1,395 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

May 03, 2025
pulisher
May 02, 2025

Leerink Partnrs Brokers Increase Earnings Estimates for CGEM - Defense World

May 02, 2025
pulisher
May 01, 2025

Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know - Yahoo Finance

May 01, 2025
pulisher
Apr 30, 2025

Cullinan Therapeutics to begin US trial of CLN-978 for treating Sjögren’s disease - Yahoo

Apr 30, 2025
pulisher
Apr 30, 2025

Barclays PLC Has $2.99 Million Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Apr 30, 2025
pulisher
Apr 30, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Holdings Reduced by Legal & General Group Plc - Defense World

Apr 30, 2025
pulisher
Apr 29, 2025

Cullinan Therapeutics to Initiate US Study of CLN-978 for Moderate to Severe Sjogren's Disease - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Cullinan Therapeutics (CGEM) Begins Study of CLN-978 for Sjogren - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Cullinan Therapeutics to Initiate Study of CLN-978, a - GlobeNewswire

Apr 29, 2025
pulisher
Apr 27, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Brokerages - Defense World

Apr 27, 2025
pulisher
Apr 25, 2025

SEC Form DEF 14A filed by Cullinan Therapeutics Inc. - Quantisnow

Apr 25, 2025
pulisher
Apr 24, 2025

Shareholders Can't Ignore US$502k Of Sales By Cullinan Therapeutics Insiders - simplywall.st

Apr 24, 2025

Cullinan Therapeutics Inc Stock (CGEM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Cullinan Therapeutics Inc Stock (CGEM) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
AHMED NADIM
President and CEO
Feb 25 '25
Sale
8.53
12,529
106,872
430,621
Michaelson Jennifer
Chief Scientific Officer
Feb 25 '25
Sale
8.53
3,756
32,039
142,004
SUMER JACQUELYN L
Chief Legal Officer
Feb 25 '25
Sale
8.53
3,756
32,039
136,895
Michaelson Jennifer
Chief Scientific Officer
Jan 06 '25
Sale
12.51
4,000
50,040
95,760
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Cap:     |  Volume (24h):